Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13085760 | 1.00 | HPGD (0.55) | HPGDEPHX1L3MBTL3L3MBTL1MEN1 | |
| SCHEMBL1094777 | 0.98 | HPGD (0.57) | HPGDEPHX1L3MBTL3L3MBTL1MEN1 | |
| SCHEMBL31209013 | 0.98 | HPGD (0.57) | HPGDEPHX1L3MBTL3L3MBTL1MEN1 | |
| SCHEMBL1094778 | 0.98 | HPGD (0.57) | HPGDEPHX1L3MBTL3L3MBTL1MEN1 | |
| SCHEMBL14196264 | 0.97 | HPGD (0.51) | HPGDEPHX1L3MBTL3L3MBTL1MEN1 | |
| SCHEMBL34473834 | 0.97 | HPGD (0.51) | HPGDEPHX1L3MBTL3L3MBTL1MEN1 | |
| SCHEMBL31209057 | 0.97 | HPGD (0.51) | HPGDEPHX1L3MBTL3L3MBTL1MEN1 | |
| SCHEMBL7388998 | 0.92 | HPGD (0.54) | HPGDEPHX1L3MBTL3L3MBTL1MEN1 | |
| SCHEMBL31208725 | 0.91 | HPGD (0.47) | HPGDEPHX1L3MBTL3L3MBTL1MEN1 | |
| SCHEMBL24672396 | 0.91 | HPGD (0.56) | HPGDEPHX1MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
| US-8828991-B2 | Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-09-09 | — | — | US | disclosed |
| US-20090082339-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368193-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | HPGD 2249/4885EPHX1 2715/4885L3MBTL3 2353/4885 |
| US-20090082339-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, MPI, TPMT | HPGD 1715/4885EPHX1 2817/4885L3MBTL3 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.